Skip to main content

Table 2 Incidence rates and hazard ratios according to DAA treatment exposure for all-cause mortality, liver-related mortality, non-liver-related mortality, and liver transplant in all 559 patients with history of decompensated cirrhosis

From: Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis

 

Not exposed to DAA

(N = 76)

Exposed to DAA

(N = 483)

Unadjusted

Multivariate analysis

IPTW

 

n/pyr

Incidence/100pyrs

(95% CI)

n/pyr

Incidence/100pyrs

(95% CI)

HR [95% CI]

HR [95% CI]

HR [95% CI]

HCC (N = 92)

20/325

6.1 (3.8–9.5)

72/1374

5.2 (4.1–6.6)

0.81 (0.47–1.38)

0.80 (0.44–1.45)

0.85 (0.50–1.47)

All cause-mortality (N = 119)

39/341

11.4 (8.1–15.6)

80/1494

5.3 (4.2–6.7)

0.40 (0.24–0.65)*

0.45 (0.24–0.84)*

0.42 (0.25–0.68)*

Liver related mortality (N = 74)

22/341

6.4 (4.0–9.8)

52/1494

3.5 (2.6–4.6)

0.50 (0.24–1.05)

0.89 (0.358–2.26)

0.60 (0.28–1.29)

Non-liver related mortality (N = 35)

11/341

3.2 (1.6–5.8)

24/1494

1.6 (1.0–2.4)

0.35 (0.16–0.75)*

0.26 (0.08–0.82)*

0.34 (0.16–0.74)*

Liver transplant (N = 36)

10/329

3.0 (1.5–5.6)

26/1414

1.8 (1.2–2.7)

0.51 (0.20–1.31)

0.53 (0.14–1.96)

0.54 (0.21–1.41)

  1. *Significant analysis associations at the p < 0.05 level